ID
22288
Description
Study part: Quality of Life. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"
Keywords
Versions (1)
- 5/29/17 5/29/17 -
Copyright Holder
Roche
Uploaded on
May 29, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
QUALITY OF LIFE Roche H0650g Breast Cancer
Similar models
QUALITY OF LIFE
- StudyEvent: ODM
C0034380 (UMLS CUI [1,2])